Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.
Houédé N, Locker G, Lucas C, Parra HS, Basso U, Spaeth D, Tambaro R, Basterretxea L, Morelli F, Theodore C, Lusuardi L, Lainez N, Guillot A, Tonini G, Bielle J, Del Muro XG.
Bmc Cancer. 2016; 16: 752-752. FI: 3,288 (Q2).
New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies.
Larrea E, Sole C, Manterola L, Goicoechea I, Armesto M, Arestin M, Caffarel M, Araujo AM, Araiz M, Fernandez-Mercado M, Lawrie CH.
International Journal Of Molecular Sciences. 2016; 17: -. FI: 3,226 (Q2).
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF, Spanish Myeloma Group / Program for the Study of Malignant Blood Diseases Therap.
Blood. 2016; 127: 1896-1906. FI: 13,164 (Q1).
mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Garros-Regulez L, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, Moreno-Cugnon L, Barrena C, Villanua J, Ruiz I, Pollard S, Lovell-Badge R, Sampron N, Garcia I, Matheu A.
Expert Opinion On Therapeutic Targets. 2016; 20: 393-405. FI: 4,873 (Q1).
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
Pérez-Valderrama, B, Arranz Arija, J A, Rodríguez Sánchez, A, Pinto Marín, A, Borrega García, P, Castellano Gaunas, D E, Rubio Romero, G, Maximiano Alonso, C, Villa Guzmán, J C, Puertas Álvarez, J L, Chirivella González, I, Méndez Vidal, M J, Juan Fita, M J, León-Mateos, L, Lázaro Quintela, M, García Domínguez, R, Jurado García, J M, Vélez de Mendizábal, E, Lambea Sorrosal, J J, García Carbonero, I, González del Alba, A, Suárez Rodríguez, C, Jiménez Gallego, P, Meana García, J A, García Marrero, R D, Gajate Borau, P, Santander Lobera, C, Molins Palau, C, López Brea, M, Fernández Parra, E M, Reig Torras, O, BASTERRETXEA BADIOLA, LAURA, Vázquez Estévez, S, González Larriba, JL.
Annals Of Oncology. 2016; 27: 706-711. FI: 11,855 (Q1).
147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study.
Arriola E, Paredes A, Gomez RG, Diz P, Constenla M, Girón CG, Amador M, Reck M, Vivanco GL.
Journal Of Thoracic Oncology. 2016; 11: -. FI: 6,595 (Q1).
Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J.
Blood. 2016; 127: 420-425. FI: 13,164 (Q1).
Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.
Kucia-Tran JA, Tulkki V, Smith S, Scarpini CG, Hughes K, Araujo AM, Yan KY, Botthof J, Pérez-Gómez E, Quintanilla M, Cuschieri K, Caffarel MM, Coleman N.
British Journal Of Cancer. 2016; 115: 212-222. FI: 6,176 (Q1).
Recent progress on colloidal metal nanoparticles as signal enhancers in nanosensing.
Abalde-Cela S, Carregal-Romero S, Coelho JP, Guerrero-Martínez A.
Advances In Colloid And Interface Science. 2016; 233: 255-270. FI: 7,223 (Q1).
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martín-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosiñol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF, Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatía.
Blood. 2016; 127: 3165-3174. FI: 13,164 (Q1).
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, TOURMALINE-MM1 Study Group.
New England Journal Of Medicine. 2016; 374: 1621-1634. FI: 72,406 (Q1).
Control of Wnt/ß-Catenin Signaling Pathway in Vivo via Light Responsive Capsules.
Ambrosone A, Marchesano V, Carregal-Romero S, Intartaglia D, Parak WJ, Tortiglione C.
Acs Nano. 2016; 10: 4828-4834. FI: 13,942 (Q1).
Prognostic role for derived neutrophil-to-lymphocyte ratio in early breast cancer.
Ocana A, Templeton AJ, Casas M, Sanchez-Arago M, Caballero R, Rodriguez A, Ruiz A, Alba E, Calvo L, Ruiz M, Santaballa A, Rodriguez C, Crespo C, Ramos M, Gracia JM, Lluch-Hernandez A, Alvarez I, Carrasco E, Amir E, Martin M.
Annals Of Oncology. 2016; 27: -. FI: 11,855 (Q1).
Budget impact analysis of the 21-gene assay (Oncotype DX (R) breast cancer) for the breast cancer treatment in the Basque Country.
Toribio MG, Mar J, Galve E, Alvarez I, Lahuerta A, Unanue G, Ibarrondo O, Novas P, Ancizar N, Larburu L, Hidalgo M, Arango JF, Churruca C, Plazaola A, Perez I, Martinez del Prado P, Dominguez S, Paisan A.
Annals Of Oncology. 2016; 27: -. FI: 11,855 (Q1).
